ZCZC
BFF-35
HEALTH-VIRUS-FRANCE-ASTRAZENECA
‘Troubling’ cases justify AstraZeneca pause: French vaccine chief
PARIS, March 16, 2021 (BSS/AFP) – A handful of “troubling” cases of blood
clots justify the suspension of the AstraZeneca vaccine, the French
government’s top vaccination advisor said Tuesday, adding that he hoped all
doubts would soon be removed about its safety.
Alain Fischer, an immunologist who heads the government’s vaccination
advisory board, said a higher number than normal of pulmonary embolism —
blood clots in the lungs — had caused alarm at the weekend.
“It’s the fact that there were a few very unusual and troubling cases
which justify this pause and the analysis,” Fischer told France Inter radio,
adding that until the weekend there had been no increase in the number of
embolism cases that are typically observed.
“It’s not lost time,” he said of the suspension. “It’s necessary time to
carry out analysis.”
President Emmanuel Macron announced the suspension Monday as France
followed the example of a host of other European countries including Germany,
Ireland and Denmark to stop using the vaccine while regulators assess its
safety.
“We are in a situation where there is a rational scientific doubt,”
Fischer said.
“I hope that this doubt will be lifted by colleagues who are working on
this issue… afterwards, obviously we will need to resume our work of
teaching and explaining, which will not be easy, I’m aware of that.”
Perceptions that the AstraZeneca vaccine is less effective than rivals
from Pfizer and Moderna and has more signficant side-effects, such as mild
flu symptoms, meant that uptake of the jab had already been slow in France.
The health ministry revealed at the beginning of March that three in four
jabs delivered by AstraZeneca had gone unused.
“Transparency is the first step in creating confidence. We’re in a
situation where everything that is known is said, and all the doubts are
raised,” Fischer said.
Experts at the World Health Organization and European regulators are to
meet Tuesday to assess the vaccine’s safety, with AstraZeneca and the British
government insisting that the reports of blood clots should not be linked to
the vaccine.
BSS/AFP/SSS/1707 hrs